secwatch.observer — SEC 8-K summary
======================================

Issuer:     DMK PHARMACEUTICALS Corp (—)
CIK:        0000887247
Form:       8-K
Filed at:   2023-05-26T23:59:59+00:00
Accession:  0001387131-23-006973
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.02, 2.01, 3.02, 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adamis closes merger with DMK Pharmaceuticals; Ebrahim Versi named CEO and Chair
--------------------------------------------------------------------------------

- Merger completed May 25; DMK shareholders received 302,815 Adamis common shares and 1,941.2 Series E Preferred shares.
- Ebrahim Versi appointed CEO and Chair; David Marguglio stepped down as CEO, remains president and COO.
- Series E Preferred convertible at 1,000 common per share; 9.99% beneficial ownership limitation; Nasdaq issuance cap.
- Board changes: Marguglio and Williams resign; Versi and Jannine Versi appointed to board.
- DMK stock options assumed: 231,490 Adamis shares; Dr. Versi holds options for 102,885 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/0001387131-23-006973-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/887247/000138713123006973/admp-8k_052423.htm
  HTML page:      https://secwatch.observer/filing/0001387131-23-006973

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer